Skip to content

TriangleGet started

← Full study record

NCT04162210 · OUTCOME

Observed Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: ug/mL
Interval / dispersion: Standard Deviation
Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; D1 SOI + 2 h of C1&3; D2 SOI + 24h of C1&3; D4, D8-15, D22 of C1&3; D1 of C2,3,4,6,9,12,18,24 & 30; D2 of C3; and EOT (~242 weeks)

What was measured

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Analysis population: Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	217

Reported measurements

C1 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	206

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00482	0.048935	Not reported	Not reported	Not reported

C1 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	202

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.50257	0.385958	Not reported	Not reported	Not reported

C1 D1, SOI + 2 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	105

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.52993	0.308119	Not reported	Not reported	Not reported

C1 D2, SOI + 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	202

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	1.24435	0.944185	Not reported	Not reported	Not reported

C1 D4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	113

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.75975	0.499179	Not reported	Not reported	Not reported

C1 D8-15

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	119

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.16905	0.163228	Not reported	Not reported	Not reported

C1 D22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	23

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00236	0.011322	Not reported	Not reported	Not reported

C2 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	8

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.27226	0.372987	Not reported	Not reported	Not reported

C2 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	189

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00314	0.025276	Not reported	Not reported	Not reported

C2 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	186

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.52055	0.431549	Not reported	Not reported	Not reported

C3 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	21

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.24057	0.283128	Not reported	Not reported	Not reported

C3 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	149

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.01507	0.091695	Not reported	Not reported	Not reported

C3 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	148

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.50649	0.396744	Not reported	Not reported	Not reported

C3 D1, SOI+ 2 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	76

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.50982	0.338394	Not reported	Not reported	Not reported

C3 D2

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	7

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.61414	0.552990	Not reported	Not reported	Not reported

C3 D2, SOI + 24 hours

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	125

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.80486	0.477242	Not reported	Not reported	Not reported

C3 D4

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	71

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.55168	0.279372	Not reported	Not reported	Not reported

C3 D8-15

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	73

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.15658	0.109425	Not reported	Not reported	Not reported

C3 D22

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.000000	Not reported	Not reported	Not reported

C4 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	4

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.44550	0.676984	Not reported	Not reported	Not reported

C4 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	124

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.01072	0.046683	Not reported	Not reported	Not reported

C4 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	122

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.48903	0.313553	Not reported	Not reported	Not reported

C6 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	16

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.20500	0.222222	Not reported	Not reported	Not reported

C6 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	90

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00247	0.011594	Not reported	Not reported	Not reported

C6 D1, EOI

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	90

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.44992	0.272831	Not reported	Not reported	Not reported

C9 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	9

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.08611	0.258333	Not reported	Not reported	Not reported

C9 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	61

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.04322	0.289200	Not reported	Not reported	Not reported

C12 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	2

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.000000	Not reported	Not reported	Not reported

C12 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	44

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.01859	0.080759	Not reported	Not reported	Not reported

C18 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	12

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.000000	0.000000	Not reported	Not reported	Not reported

C18 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	25

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00884	0.025477	Not reported	Not reported	Not reported

C24 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	1

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.000000	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

C24 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	14

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.000000	Not reported	Not reported	Not reported

C30 D1

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	1

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.000000	NA	Not reported	Not reported	Standard Deviation is not evaluable for a single participant.

C30 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	6

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.000000	Not reported	Not reported	Not reported

C36 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	3

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.000000	Not reported	Not reported	Not reported

C42 D1, Pre-dose

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	1

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.00000	0.00000	Not reported	Not reported	Not reported

EOT (~242 weeks)

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	128

Values in ug/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	0.03551	0.114319	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
0.048935
value
0.00482
denoms
counts
group Id
OG000
value
206
units
Participants
title
C1 D1, Pre-dose
categories
measurements
group Id
OG000
spread
0.385958
value
0.50257
denoms
counts
group Id
OG000
value
202
units
Participants
title
C1 D1, EOI
categories
measurements
group Id
OG000
spread
0.308119
value
0.52993
denoms
counts
group Id
OG000
value
105
units
Participants
title
C1 D1, SOI + 2 hours
categories
measurements
group Id
OG000
spread
0.944185
value
1.24435
denoms
counts
group Id
OG000
value
202
units
Participants
title
C1 D2, SOI + 24 hours
categories
measurements
group Id
OG000
spread
0.499179
value
0.75975
denoms
counts
group Id
OG000
value
113
units
Participants
title
C1 D4
categories
measurements
group Id
OG000
spread
0.163228
value
0.16905
denoms
counts
group Id
OG000
value
119
units
Participants
title
C1 D8-15
categories
measurements
group Id
OG000
spread
0.011322
value
0.00236
denoms
counts
group Id
OG000
value
23
units
Participants
title
C1 D22
categories
measurements
group Id
OG000
spread
0.372987
value
0.27226
denoms
counts
group Id
OG000
value
8
units
Participants
title
C2 D1
categories
measurements
group Id
OG000
spread
0.025276
value
0.00314
denoms
counts
group Id
OG000
value
189
units
Participants
title
C2 D1, Pre-dose
categories
measurements
group Id
OG000
spread
0.431549
value
0.52055
denoms
counts
group Id
OG000
value
186
units
Participants
title
C2 D1, EOI
categories
measurements
group Id
OG000
spread
0.283128
value
0.24057
denoms
counts
group Id
OG000
value
21
units
Participants
title
C3 D1
categories
measurements
group Id
OG000
spread
0.091695
value
0.01507
denoms
counts
group Id
OG000
value
149
units
Participants
title
C3 D1, Pre-dose

denoms

counts
group Id
OG000
value
217
units
Participants

description

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

dispersion Type

Standard Deviation

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin

param Type

MEAN

population Description

Pharmacokinetic population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points.

reporting Status

POSTED

time Frame

Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; D1 SOI + 2 h of C1&3; D2 SOI + 24h of C1&3; D4, D8-15, D22 of C1&3; D1 of C2,3,4,6,9,12,18,24 & 30; D2 of C3; and EOT (~242 weeks)

title

Observed Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)

type

SECONDARY

unit Of Measure

ug/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice